Adherex Technologies, Inc.

Quick facts

Phase 1 pipeline

• ADH -1 and capecitabine · Oncology
  ADH-1 is a vasopressin receptor antagonist, and capecitabine is a thymidylate synthase inhibitor.
• ADH -1 and carboplatin · Oncology
  Antiangiogenic and platinum-based chemotherapy
• ADH -1 and docetaxel · Oncology
  ADH-1 is an angiostatic peptide that inhibits angiogenesis by binding to heparin sulfate proteoglycans on the surface of endothelial cells, while docetaxel is a microtubule inhibitor that blocks cell division.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Adherex Technologies, Inc. portfolio CI brief
• Adherex Technologies, Inc. pipeline updates RSS